Other
Gastro-Oesophageal Reflux Disease
0
Pipeline Programs↗
0
Active Trials↗
3
Companies Involved↗
Gastro-oesophageal Reflux Disease is an early-stage landscape with 0 programs across 3 companies. The most active players are Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Johnson & Johnson, Studio Osteopatico Busto Arsizio.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
4
clinical trials
Terminated2 · 50%
Unknown status1 · 25%
Completed1 · 25%
Clinical Trials
Trial Activity
A Study of Cisapride in Patients With Symptomatic Gastro-Oesophageal Reflux Disease
Terminated·
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 4·NCT01281553·6 enrolled
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.·Phase 4·NCT01281553·6 enrolledData sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)